ResearchSystematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases
ResearchPrevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey
ResearchSubcutaneous infliximab in pediatric inflammatory bowel disease: Sustained remission, predictable pharmacokinetics, and real-world US implementation
ResearchComparable 12-Week and Superior 24-Week Remission With Risankizumab vs Ustekinumab for Crohn's-Like Disease of the Pouch
ResearchUpadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition
ResearchThe Impact of Gender, Rank, and Race on Industry Payments in Pediatric and Adult Gastroenterology
ResearchUstekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
ResearchEarly intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-UC study
ResearchPatient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease-A Multinational Survey
ResearchEvaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion
ResearchSingle-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease
ResearchFailure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease